Memantine affects cognitive flexibility in the morris water maze

Journal of Alzheimer's Disease

Volumn 27, Issue 3, 2011, Pages 477-482

  Saab, Bechara J ^a,b   Luca, Ruxandra M ^b   Yuen, Wing B ^b   Saab, Adam M P ^b,c   Roder, John C ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Alzheimer's disease; cognitive disorder; cognitive flexibility; dopamine; excitotoxicity; GABA(A); hippocampus; learning and memory; memantine; mental flexibility; mice; mouse; muscarinic cholinergic system; neurotoxicity; NMDAR; platform re location water maze; prefrontal cortex

Indexed keywords

4 AMINOBUTYRIC ACID; DOPAMINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ARTICLE; BRAIN FUNCTION; CHOLINERGIC SYSTEM; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; HIPPOCAMPUS; LEARNING; MALE; MAZE TEST; MEMORY; MOUSE; NEUROTRANSMISSION; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; SPATIAL MEMORY; TREATMENT OUTCOME;

EID: 82555195178     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-110650     Document Type: Article

References (29)

1. Bossen AL, Specht JK, McKenzie SE (2009) Needs of people with early-stage Alzheimer's disease: Reviewing the evidence. J Gerontol Nurs 35, 8-15.
2. Herrmann N, Gauthier S (2008) Diagnosis and treatment of dementia: 6. Management of severe Alzheimer disease.CMAJ 179, 1279-1287.
3. Sierksma AS, van den Hove DL, Steinbusch HW, Prickaerts J (2010) Major depression, cognitive dysfunction and Alzheimer's disease: Is there a link? Eur J Pharmacol 626, 72-82.
4. Starkstein SE, Mizrahi R, Power BD (2008) Depression in Alzheimer's disease: Phenomenology, clinical correlates and treatment. Int Rev Psychiatry 20, 382-388.
5. Wuwongse S, Chang RC, Law AC (2010) The putative neurodegenerative links between depression and Alzheimer's disease. Prog Neurobiol 91, 362-375.
6. Marazziti D, Consoli G, Picchetti M, Carlini M, Faravelli L (2010) Cognitive impairment in major depression. Eur JPharmacol 626, 83-86.
7. Lipton SA (2004) Failures and successes of NMDA receptor antagonists: Molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRx 1, 101-110. (Pubitemid 46589343)
8. Rammes G, Rupprecht R, Ferrari U, Zieglgansberger W, Parsons CG (2001) The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other aminoalkyl- cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a noncompetitive manner. Neurosci Lett 306, 81-84. (Pubitemid 32524303)
9. Drever BD, Anderson WG, Johnson H, O'Callaghan M, Seo S, Choi DY, Riedel G, Platt B (2007) Memantine acts as a cholinergic stimulant in the mouse hippocampus. J Alzheimers Dis 12, 319-333.
10. Aracava Y, Pereira EF, Maelicke A, Albuquerque EX (2005) Memantine blocks alpha7.* nicotinic acetylcholine receptors more potently than n-methyl-D-aspartate receptors in rat hippocampal neurons. J Pharmacol Exp Ther 312, 1195-1205. (Pubitemid 40293781)
11. Hesselink MB, De Boer AG, Breimer DD, Danysz W (1999) Adaptations of NMDA and dopamine D2, but not of muscarinic receptors following 14 days administration of uncompetitive NMDA receptor antagonists. J Neural Transm 106, 409-421. (Pubitemid 29273882)
12. Spanagel R, Eilbacher B,WilkeR(1994) Memantine-induced dopamine release in the prefrontal cortex and striatum of the rat-a pharmacokinetic microdialysis study. Eur J Pharmacol 262, 21-26. (Pubitemid 24271832)
13. Molinaro G, Battaglia G, Riozzi B, Di Menna L, Rampello L, Bruno V, Nicoletti F (2009) Memantine treatment reduces the expression of the K(+)/Cl(-) cotransporter KCC2 in the hippocampus and cerebral cortex, and attenuates behavioural responses mediated by GABA(A) receptor activation in mice. Brain Res 1265, 75-79.
14. Creeley CE, Wozniak DF, Nardi A, Farber NB, Olney JW (2008) Donepezil markedly potentiates memantine neurotoxicity in the adult rat brain. Neurobiol Aging 29, 153-167.
15. Danysz W, Parsons CG (2003) The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: Preclinical evidence. Int J Geriatr Psychiatry 18, S23-S32. (Pubitemid 37150475)
16. Gardoni F, Di LucaM(2006) Newtargets for pharmacological intervention in the glutamatergic synapse. Eur J Pharmacol 545, 2-10. (Pubitemid 44215874)
17. Barnes CA, Danysz W, Parsons CG (1996) Effects of the uncompetitive NMDA receptor antagonist memantine on hippocampal long-term potentiation, short-term exploratory modulation and spatial memory in awake, freely moving rats. Eur J Neurosci 8, 565-571. (Pubitemid 26090761)
18. Chen HS,Wang YF, Rayudu PV, Edgecomb P, Neill JC, Segal MM, Lipton SA, Jensen FE (1998) Neuroprotective concentrations of the N-methyl-D-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation. Neuroscience 86, 1121-1132. (Pubitemid 28318538)
19. Minkeviciene R, Banerjee P, Tanila H (2008) Cognitionenhancing and anxiolytic effects of memantine. Neuropharmacology 54, 1079-1085.
20. Block F, Schwarz M (1996) Memantine reduces functional and morphological consequences induced by global ischemia in rats. Neurosci Lett 208, 41-44. (Pubitemid 26130443)
21. Camarasa J, Rodrigo T, Pubill D, Escubedo E (2010) Memantine is a useful drug to prevent the spatial and non-spatial memory deficits induced by methamphetamine in rats. Pharmacol Res 62, 450-456.
22. Lukoyanov NV, Paula-Barbosa MM (2001) Memantine, but not dizocilpine, ameliorates cognitive deficits in adult rats withdrawn from chronic ingestion of alcohol. Neurosci Lett 309, 45-48. (Pubitemid 32728256)
23. Minkeviciene R, Banerjee P, Tanila H (2004) Memantine improves spatial learning in a transgenic mouse model of Alzheimer's disease. J Pharmacol Exp Ther 311, 677-682. (Pubitemid 39391555)
24. Rueda N, Llorens-Martin M, Florez J, Valdizan E, Banerjee P, Trejo JL, Martinez-Cue C (2010) Memantine normalizes several phenotypic features in the Ts65Dn mouse model of down syndrome. J Alzheimers Dis 21, 277-290.
25. Saab BJ, Saab AM, Roder JC (2011) Statistical and theoretical considerations for the platform re-location water maze. J Neurosci Methods 198, 44-52.
26. Kornhuber J, Kennepohl EM, Bleich S, Wiltfang J, Kraus T, Reulbach U, Meineke I (2007) Memantine pharmacotherapy: A naturalistic study using a population pharmacokinetic approach. Clin Pharmacokinet 46, 599-612. (Pubitemid 47025360)
27. Morris RG, Anderson E, Lynch GS, Baudry M (1986) Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. Nature 319, 774-776. (Pubitemid 16145031)
28. Saab BJ, Maclean AJ, Kanisek M, Zurek AA, Martin LJ, Roder JC, Orser BA (2010) Short-term memory impairment after isoflurane in mice is prevented by the alpha5 gammaaminobutyric acid type A receptor inverse agonist L-655,708. Anesthesiology 113, 1061-1071.
29. Kehagia AA, Murray GK, Robbins TW (2010) Learning and cognitive flexibility: frontostriatal function and monoaminergic modulation. Curr Opin Neurobiol 20, 199-204.